NeoSci Ventures reaches $53M first close for debut fund
The Singapore-based firm targets early-stage therapeutics and the convergence of biology with AI and data tools.
Singapore-based venture builder NeoSci Ventures has reached a first close of $53 million for its debut institutional vehicle [1].
The fund targets investments across therapeutics alongside technology companies operating where biology converges with artificial intelligence, data, and laboratory tools [1]. Backers participating in the initial close include Singapore state investor EDBI, Taiwan's National Development Fund, Catcher Technology, and Crescendas Group [1].
Founding managing partner Daphne Teo and founding chief scientist Timothy Lu oversee the firm, which functions as both an investor and a venture creator [1]. Alongside capital deployment, NeoSci Ventures has already co-founded a portfolio company named Protuoso [1].
According to an announcement covered by e27, the firm aims to direct its capital toward computational platforms and early-stage life science assets [1].
Questions and answers
How much has NeoSci Ventures raised?
NeoSci Ventures secured a $53 million first close for its inaugural fund.
Who are the key backers of the fund?
Institutional participants include the National Development Fund, EDBI, Catcher Technology, and Crescendas Group.
What areas does NeoSci Ventures invest in?
The vehicle targets therapeutics and startups at the intersection of biological science, artificial intelligence, and data.
Companies & investors in this story
Sources
- 1.Taiwan and Singapore back NSV’s US$53M bet on Asia’s biotech pipeline — e27, Nov 3, 2026
- 2.Singapore’s NSV raises $53M for inaugural biotech fund, targeting US, Asia — TNGlobal, Nov 3, 2026
